Merck’s Sotatercept Hits Phase III Marks In Mid-Stage PAH Patients

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The pharma’s pulmonary arterial hypertension candidate, touted as a future blockbuster seller, showed benefit on six-minute walk distance and several secondary endpoints in Phase III STELLAR.

Merck & Co.
Merck shows sotatercept can offer benefit in PAH patients

Merck & Co., Inc. hit a key milestone in advancing its cardiovascular pipeline on 10 October, announcing a successful Phase III trial for sotatercept, a reverse-remodeling agent proposed to rebalance TGF-beta superfamily signaling, in mid-stage pulmonary arterial hypertension (PAH) patients. The pharma said it will move “with urgency” in speaking with regulators about an approval pathway for sotatercept.

In an interview, Merck chief medical officer Eliav Barr said the company feels that urgency because PAH care lacks for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D